SCA
CSTL icon

Spearhead Capital Advisors’s Castle Biosciences CSTL Stock Holding History

Spearhead Capital Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,437
Closed -$334K – 186
2022
Q1 		$334K Buy
+7,437
New +$307K 0.04% 118

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Spearhead Capital Advisors's CSTL Position: Q2 2022 in Review

Spearhead Capital Advisors sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 7,437 shares — an estimated $334K sold.

Spearhead Capital Advisors first reported a position in CSTL in Q1 2022 and held it in 1 quarter. The position peaked at $334K in Q1 2022. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Spearhead Capital Advisors reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 7,437 Castle Biosciences shares in Q2 2022, an estimated $334K.
  • Spearhead Capital Advisors first reported a position in Castle Biosciences in Q1 2022 and held it in 1 quarter.
  • Spearhead Capital Advisors's Castle Biosciences position peaked at $334K in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Spearhead Capital Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.